Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Wongchenko

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III TrialRebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, et al.
Cell Death and Differentiation|March 3, 2019
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptationJason E Long, Matthew J Wongchenko, Dorothee Nickles, et al.
The Lancet. Oncology|August 13, 2017
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialSung-Bae Kim, Rebecca Dent, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus VemurafenibMatthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic MelanomaYibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Cancer Cell|March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
Nature Communications|September 23, 2023
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancerLucia Taraborrelli, Yasin Şenbabaoğlu, Lifen Wang, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III TrialRebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, et al.
Cell Death and Differentiation|March 3, 2019
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptationJason E Long, Matthew J Wongchenko, Dorothee Nickles, et al.
The Lancet. Oncology|August 13, 2017
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialSung-Bae Kim, Rebecca Dent, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus VemurafenibMatthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic MelanomaYibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Cancer Cell|March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
Nature Communications|September 23, 2023
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancerLucia Taraborrelli, Yasin Şenbabaoğlu, Lifen Wang, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Pageof 2